Oncotelic Therapeutics Expands into AI-Enhanced Robotics with TechForce Partnership

Oncotelic Therapeutics (OTCQB: OTLC) is moving beyond its roots as a clinical-stage biotechnology company into the quickly expanding intersection of artificial intelligence and industrial automation. Through two closely aligned announcements, the firm has unveiled a strategic partnership with TechForce Robotics, which positions it to commercialize a next-generation, AI-enhanced platform created for regulated pharmaceutical environments.

At the core of this pivot is Oncotelic’s proprietary PDAOAI platform, an AI-driven system designed to improve compliance, monitoring, and operational intelligence. By integrating this innovation with TechForce Robotics’ hardware and manufacturing expertise, the companies aim to deliver a GMP-compliant robotics solution capable of automating critical workflows in pharmaceutical production and laboratory settings. This move into robotics represents a significant expansion for Oncotelic, which has traditionally focused on oncology and immunotherapy drug development.

The partnership highlights the growing convergence of biotech and automation, as pharmaceutical companies seek to enhance efficiency and regulatory compliance. Oncotelic’s PDAOAI platform leverages artificial intelligence to monitor processes, ensure adherence to Good Manufacturing Practices (GMP), and provide real-time operational insights. Combined with TechForce Robotics’ hardware capabilities, the solution could address key pain points in pharmaceutical manufacturing, including contamination risks, human error, and labor shortages.

Oncotelic remains a clinical-stage biopharmaceutical company focused on high-unmet-need cancers and rare pediatric indications. The company’s pipeline includes innovative late-stage therapeutic candidates, and it benefits from the extensive patent portfolio of its CEO, Dr. Vuong Trieu, who has filed more than 150 patent applications and holds 39 issued U.S. patents. Beyond its internal programs, Oncotelic also licenses and codevelops select drug candidates through joint ventures. Currently, Oncotelic owns 45% of GMP Bio, a joint venture under Trieu’s leadership that is advancing its own pipeline of drug candidates complementary to Oncotelic’s strategic position in oncology and rare disease therapeutics.

The expansion into AI-enhanced robotics does not signal a departure from Oncotelic’s core mission but rather a diversification into adjacent technologies that could support both its own operations and the broader pharmaceutical industry. The company’s ability to leverage its AI expertise in a new domain may open additional revenue streams and strategic opportunities. For more information on the partnership, interested parties can view the full article at this link.

This development underscores the growing importance of automation and AI in life sciences, as companies seek to modernize manufacturing processes and maintain competitive advantage. The latest news and updates relating to OTLC are available in the company’s newsroom at this link.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Oncotelic Therapeutics Expands into AI-Enhanced Robotics with TechForce Partnership.

The post Oncotelic Therapeutics Expands into AI-Enhanced Robotics with TechForce Partnership appeared first on citybuzz.